Hanafusa H, et al. (2022) LRRK1-mediated NDEL1 phosphorylation promotes cilia disassembly via dynein-2-driven retrograde intraflagellar transport. J Cell Sci 36254578

This page summarizes selected information from the record referenced above and curated into PhosphoSitePlus®, a comprehensive online resource for the study of protein post-translational modifications (NAR, 2015, 43:D512-20). To learn more about the scope of PhosphoSitePlus®, click here.

Information from this record has been curated, but not yet edited in PhosphoSitePlus® and may be incomplete.

Click on the protein name to open the protein page, and on the RSD number to open the site page.

Download

T1427-p - LRRK1 (human) ▲

Modsite: GALGVEGtPGyQAPE SwissProt Entrez-Gene Orthologous residues LRRK1 (human): T1427‑p, LRRK1 (mouse): T1427‑p Characterization Methods used to characterize site in vivo:  immunoassay, phospho-antibody Relevant cell lines - cell types - tissues:  hTERT-RPE1 (epithelial) Cellular systems studied:  cell lines Species studied:  human Upstream Regulation Treatments, proteins and their effect on site modification:  Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes serum increase Downstream Regulation Effect of modification (function):  enzymatic activity, induced, molecular association, regulation Effect of modification (process):  cytoskeletal reorganization Modification regulates interactions with:  Interacting molecule Interacting domains Effect Consequences (function) Consequences (process) Detection assays DYNC2I2 (human) Induces co-immunoprecipitation DYNC2I1 (human) Induces co-immunoprecipitation

S1817-p - LRRK1 (human) ▲

Modsite: GDSIADVsIMYSEEL SwissProt Entrez-Gene Orthologous residues LRRK1 (human): S1817‑p, LRRK1 (mouse): S1816‑p Characterization Methods used to characterize site in vivo:  immunoassay, phospho-antibody Relevant cell lines - cell types - tissues:  hTERT-RPE1 (epithelial) Cellular systems studied:  cell lines Species studied:  human Upstream Regulation Potential in vivo enzymes for site:  Type Enzyme Evidence Notes KINASE PLK1 (human) pharmacological inhibitor of upstream enzyme Treatments, proteins and their effect on site modification:  Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes serum increase BI2536 serum inhibit treatment-induced increase Downstream Regulation Effect of modification (function):  enzymatic activity, induced, molecular association, regulation Effect of modification (process):  cytoskeletal reorganization Modification regulates interactions with:  Interacting molecule Interacting domains Effect Consequences (function) Consequences (process) Detection assays DYNC2I1 (human) Induces co-immunoprecipitation DYNC2I2 (human) Induces co-immunoprecipitation

S95-p - NDEL1 (human) ▲
Modsite: AQSYKQVsVLEDDLS SwissProt Entrez-Gene Orthologous residues NDEL1 (human): S95‑p, NDEL1 iso2 (human): S95‑p, NDEL1 iso3 (human): S95‑p, NDEL1 (mouse): S95‑p, NDEL1 (rat): S95‑p Characterization Methods used to characterize site in vivo:  mass spectrometry (in vitro) Enzymes shown to modify site in vitro:  Type Enzyme KINASE LRRK1 (human)

T132-p - NDEL1 (human) ▲
Modsite: LERAKRAtIVsLEDF SwissProt Entrez-Gene Orthologous residues NDEL1 (human): T132‑p, NDEL1 iso2 (human): T132‑p, NDEL1 iso3 (human): T132‑p, NDEL1 (mouse): T132‑p, NDEL1 (rat): T132‑p Characterization Methods used to characterize site in vivo:  mass spectrometry (in vitro) Enzymes shown to modify site in vitro:  Type Enzyme KINASE LRRK1 (human)

S155-p - NDEL1 (human) ▲

Modsite: ERNAFLEsELDEKEs SwissProt Entrez-Gene Orthologous residues NDEL1 (human): S155‑p, NDEL1 iso2 (human): S155‑p, NDEL1 iso3 (human): S155‑p, NDEL1 (mouse): S155‑p, NDEL1 (rat): S155‑p Characterization Methods used to characterize site in vivo:  immunoassay, mass spectrometry (in vitro), mutation of modification site, phospho-antibody Relevant cell lines - cell types - tissues:  E.coli (bacterial), hTERT-RPE1 (epithelial) Cellular systems studied:  cell lines Species studied:  bacteria, human Enzymes shown to modify site in vitro:  Type Enzyme KINASE LRRK1 (human) Upstream Regulation Potential in vivo enzymes for site:  Type Enzyme Evidence Notes KINASE LRRK1 (human) transfection of wild-type enzyme, transfection of constitutively active enzyme, transfection of inactive enzyme, phospho-antibody, siRNA inhibition of enzyme Treatments, proteins and their effect on site modification:  Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes serum increase siRNA serum inhibit treatment-induced increase LRRK1 siRNA BI2536 serum inhibit treatment-induced increase

S162-p - NDEL1 (human) ▲
Modsite: sELDEKEsLLVsVQR SwissProt Entrez-Gene Orthologous residues NDEL1 (human): S162‑p, NDEL1 iso2 (human): S162‑p, NDEL1 iso3 (human): S162‑p, NDEL1 (mouse): S162‑p, NDEL1 (rat): S162‑p Characterization Methods used to characterize site in vivo:  mass spectrometry (in vitro) Enzymes shown to modify site in vitro:  Type Enzyme KINASE LRRK1 (human)

S166-p - NDEL1 (human) ▲
Modsite: EKEsLLVsVQRLKDE SwissProt Entrez-Gene Orthologous residues NDEL1 (human): S166‑p, NDEL1 iso2 (human): S166‑p, NDEL1 iso3 (human): S166‑p, NDEL1 (mouse): S166‑p, NDEL1 (rat): S166‑p Characterization Methods used to characterize site in vivo:  mass spectrometry (in vitro) Enzymes shown to modify site in vitro:  Type Enzyme KINASE LRRK1 (human)

S213-p - NDEL1 (human) ▲
Modsite: MDsAVQAsLsLPAtP SwissProt Entrez-Gene Orthologous residues NDEL1 (human): S213‑p, NDEL1 iso2 (human): S213‑p, NDEL1 iso3 (human): S213‑p, NDEL1 (mouse): S213‑p, NDEL1 (rat): S213‑p Characterization Methods used to characterize site in vivo:  mass spectrometry (in vitro) Enzymes shown to modify site in vitro:  Type Enzyme KINASE LRRK1 (human)